The organ that processes everything.
The liver is the primary site of testosterone clearance, T4-to-T3 conversion, NAD+ metabolism, IGF-1 production, and lipid synthesis. Almost every optimization protocol touches hepatic function. Almost no optimization protocol monitors it adequately.
I. The liver's central role in optimization protocols.
IGF-1 production. Approximately 75% of circulating IGF-1 is produced in the liver under growth hormone stimulation. Hepatic IGF-1 production requires adequate GH receptor density and intact hepatic health. Impaired hepatic function reduces the IGF-1 response to GH secretagogue protocols, meaning a patient with subclinical hepatic disease may appear refractory to peptide dosing when the real constraint is hepatic output capacity. verified
Testosterone clearance. Testosterone is metabolized in the liver primarily by reduction via 5-alpha and 5-beta reductase enzymes, and by conjugation via glucuronidation and sulfation. Impaired hepatic function reduces testosterone clearance and can elevate free testosterone unexpectedly, producing symptoms of androgen excess even at physiological TRT doses. verified
Aromatase activity. Significant aromatase activity occurs within hepatic tissue itself. Hepatic aromatization contributes meaningfully to testosterone-to-estradiol conversion. The patient with hepatic steatosis or early fibrosis may have elevated estradiol not from peripheral aromatization alone, but from impaired hepatic estrogen clearance compounding the hepatic aromatase contribution. verified
T4 to T3 conversion. The liver is the primary site of peripheral deiodinase activity converting thyroxine (T4) to the active form triiodothyronine (T3). Hepatic disease reduces T3 production and elevates reverse T3 (rT3). A patient with normal TSH and low T3 who is symptomatic for hypothyroidism may have a hepatic conversion deficit rather than a pituitary or thyroid failure. verified
Lipid metabolism. All major lipoproteins, including LDL, HDL, and VLDL, are produced and cleared in the liver. Hepatic steatosis, commonly called fatty liver disease, is the most prevalent metabolic liver condition and is a primary driver of elevated ApoB and cardiovascular risk. A protocol that optimizes testosterone and GH while ignoring hepatic steatosis is optimizing upstream while the downstream cardiovascular risk compounds. verified
II. NAFLD and the optimization patient.
Non-alcoholic fatty liver disease (NAFLD) affects approximately 25% of US adults. In obese patients the prevalence rises to 60 to 80%. In patients with insulin resistance, prevalence is extremely high, and insulin resistance is one of the most common presenting features of the optimization-seeking patient. verified [I]
NAFLD exists on a spectrum: simple steatosis (reversible with metabolic intervention) progresses to non-alcoholic steatohepatitis (NASH, characterized by hepatocyte inflammation and ballooning), then to fibrosis, and ultimately to cirrhosis. The transition from steatosis to NASH is not reliably predicted by standard blood panels. verified
GH secretagogue protocols have a relevant secondary benefit here. Growth hormone is lipolytic in the liver. GH secretagogue protocols reduce hepatic fat as a secondary effect of their primary GH-stimulating mechanism. This is clinically beneficial. It requires monitoring: rapid hepatic fat mobilization can transiently elevate transaminases during the first 8 to 12 weeks of a GH secretagogue protocol. A mild transaminase elevation in this context is not cause for discontinuation but it must be evaluated in context. inferred from GH physiology
III. Oral vs. injectable testosterone and liver health.
Oral testosterone (testosterone undecanoate, Jatenzo). Oral testosterone undergoes first-pass hepatic metabolism. Oral formulations are associated with transient transaminase elevation and require hepatic monitoring throughout use. This is a real consideration for the subset of patients who prefer oral administration. verified
Injectable testosterone (cypionate, enanthate). Injectable testosterone bypasses first-pass hepatic metabolism entirely. Hepatotoxicity is not a meaningful concern with standard injectable TRT at physiological replacement doses. The clinical evidence does not support hepatic monitoring beyond standard metabolic panel surveillance for injectable TRT at physiological doses. verified [IV]
The Category Error That Has Persisted for Decades
The historical concern about testosterone and liver toxicity derived from 17-alpha-alkylated oral anabolic steroids such as methyltestosterone and oxandrolone, not from injectable testosterone esters. The 17-alpha-alkylation renders a compound resistant to first-pass hepatic degradation, producing direct hepatotoxic load. Injectable testosterone cypionate carries no such structural modification and no such mechanism. Applying the hepatotoxicity concern of 17-alpha-alkylated compounds to injectable testosterone cypionate is a category error. It has confused patients and clinicians for decades, led to unnecessary monitoring burdens on injectable TRT, and obscured the actual hepatic consideration in optimization medicine: not TRT hepatotoxicity, but pre-existing hepatic steatosis reducing TRT clearance and elevating estradiol.
IV. Hepatic monitoring protocol.
Baseline panel. ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin, and total protein. This seven-marker panel establishes hepatic synthetic function, hepatocellular integrity, biliary function, and early oxidative stress signal. Order this at baseline before initiating any optimization protocol. verified
ALT-to-platelet ratio index (APRI). A validated, non-invasive surrogate for hepatic fibrosis. APRI below 0.5 makes significant fibrosis unlikely. APRI above 1.5 warrants further evaluation. The formula: AST divided by the upper limit of normal for AST, divided by platelet count in units of 10^9/L, multiplied by 100. verified [II]
FIB-4 score. Age multiplied by AST, divided by platelet count multiplied by the square root of ALT. FIB-4 below 1.3 indicates low fibrosis risk. FIB-4 above 2.67 indicates high fibrosis risk and warrants formal hepatology evaluation. verified [III]
Recheck timing. Repeat transaminases at 6 to 8 weeks after starting any new oral medication with hepatic metabolism, at 3 months after initiating a GH secretagogue protocol, and annually thereafter if the patient is stable on a fixed protocol.
V. Hepatoprotective compounds in the optimization stack.
BPC-157. Hepatoprotective effects have been demonstrated in multiple rodent models of hepatotoxin-induced liver injury. BPC-157 exhibits anti-inflammatory activity at the hepatic level and promotes hepatocyte regeneration. It is one of the compounds in the Pivotal stack that has direct hepatic mechanism data, not merely incidental hepatic effects. verified [V]
GHK-Cu. GHK-Cu upregulates antioxidant gene expression, including superoxide dismutase (SOD) and catalase. This antioxidant gene activation reduces oxidative hepatic injury, which is a key driver of the progression from simple steatosis to NASH. verified
NAD+ precursors. Sirtuin activity, particularly SIRT1 and SIRT3, has direct hepatoprotective effects. Sirtuins reduce hepatic steatosis and improve mitochondrial function in hepatocytes. NAD+ precursor supplementation supports sirtuin activity and has been studied in the context of NAFLD as a metabolic intervention. verified
MOTS-c. AMPK activation in the liver reduces de novo lipogenesis and promotes hepatic fat oxidation. AMPK activation is the primary mechanism by which MOTS-c reduces hepatic steatosis. In a patient with metabolic syndrome and fatty liver, MOTS-c addresses a root cause of the hepatic condition, not a downstream marker. verified
VI. When to refer.
ALT or AST above 3 times the upper limit of normal on repeated testing is a hepatology referral threshold. A single elevated value during a protocol transition is not necessarily referral-worthy; a persistent elevation across two consecutive draws 4 weeks apart is.
ALT persistently above 60 IU/L in men or 45 IU/L in women without a clear precipitating cause warrants hepatology evaluation, not watchful waiting.
FIB-4 above 2.67 is a referral trigger for transient elastography (FibroScan) or formal hepatology evaluation. Do not continue adding compounds with hepatic metabolic interaction when the fibrosis risk score is high without characterizing the hepatic status first.
Suspected NASH, defined as elevated transaminases with insulin resistance and significant steatosis on imaging, warrants hepatology referral before initiating GH secretagogues or adding compounds that affect hepatic metabolism significantly.
The optimization protocol does not pause while waiting for hepatology. It adjusts. Remove hepatically-cleared compounds or compounds with significant hepatic metabolic interaction. Restart after hepatic status has been characterized by a specialist. Adjustment is not discontinuation; it is precision.